Scherneck S, Ulrich R, Feunteun J
Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Virus Genes. 2001 Jan;22(1):93-101. doi: 10.1023/a:1008190504521.
The hamster polyomavirus (HaPV) was first described in 1967 as a virus associated with skin epithelioma of the Syrian hamster. The tumors appear spontaneously in a hamster colony bred in Berlin-Buch (HaB). Virus particles isolated from skin epitheliomas cause lymphoma and leukemia when injected into newborn hamsters from a distinct colony bred in Potsdam, Germany (HaP). The viral genome has been totally sequenced and the overall genetic organization establishes HaPV as a member of the polyomaviruses. HaPV is a second example of an middle T (MT) antigen encoding polyomavirus and nucleotide sequence homologies designates the mouse polyomavirus (Py) as the closest relative. Lymphomas induced by HaPV in HaP hamsters do not contain virus particles but instead accumulate different amounts of nonrandomly deleted free and/or integrated viral genomes. Transgenic mice produced by microinjection of HaPV DNA into the pronucleus of fertilized eggs of Gat: NMRI mice developed both, epitheliomas and lymphomas. Both tumor types contain extrachromosomal DNA. HaPV DNA was found to replicate in hamster lymphoid and fibroblast cell lines. Fully reproductive cycles could be detected only in GD36 lymphoblastic leukemia cells. HaPV carries the full transforming properties of a polyomavirus in vitro. Immortalization of primary rat cells is essentially carried out by the HaPV large T (LT) antigen and coexpression of HaPV MT and HaPV small T (ST) antigen is required for full transformation of rat fibroblasts. The preferential binding of HaPV MT to c-Fyn, a Src family kinase, has been proposed as a mechanism leading to lymphoid malignancies. Heterologous expression of HaPV-VP1 allowed the formation of virus like particles (VLPs) resembling HaPV particles. The high flexibility of HaPV-VP1 for insertion of foreign peptides offers a broad range of potential applications, especially in vaccine development.
仓鼠多瘤病毒(HaPV)于1967年首次被描述为一种与叙利亚仓鼠皮肤上皮瘤相关的病毒。肿瘤在柏林-布赫(HaB)饲养的仓鼠群体中自发出现。从皮肤上皮瘤中分离出的病毒颗粒,注射到德国波茨坦一个不同群体饲养的新生仓鼠(HaP)体内时,会引发淋巴瘤和白血病。该病毒基因组已被完全测序,整体遗传结构确定HaPV为多瘤病毒家族的一员。HaPV是编码中T(MT)抗原的多瘤病毒的第二个例子,核苷酸序列同源性表明小鼠多瘤病毒(Py)是其最亲近的亲属。HaPV在HaP仓鼠中诱导的淋巴瘤不含病毒颗粒,而是积累了不同数量的非随机缺失的游离和/或整合的病毒基因组。通过将HaPV DNA显微注射到Gat:NMRI小鼠受精卵的原核中产生的转基因小鼠,会同时发生上皮瘤和淋巴瘤。这两种肿瘤类型都含有染色体外DNA。发现HaPV DNA可在仓鼠淋巴细胞和成纤维细胞系中复制。仅在GD36淋巴细胞白血病细胞中能检测到完整的复制周期。HaPV在体外具有多瘤病毒的完全转化特性。原代大鼠细胞的永生化主要由HaPV大T(LT)抗原完成,而HaPV MT和HaPV小T(ST)抗原的共表达是大鼠成纤维细胞完全转化所必需的。有人提出HaPV MT与Src家族激酶c-Fyn的优先结合是导致淋巴恶性肿瘤的一种机制。HaPV-VP1的异源表达允许形成类似于HaPV颗粒的病毒样颗粒(VLP)。HaPV-VP1插入外源肽的高度灵活性提供了广泛的潜在应用,特别是在疫苗开发方面。